Genmab — Juni 2019
-
Genmab Announces U.S. FDA Approval of DARZALEX
(daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company AnnouncementDARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Approval based on Phase III MAIA study
Copenhagen, Denmark; June 27, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) -
offer their patients the option to add DARZALEX to this regimen in the U.S.,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
The approval was based on data from the Phase III MAIA (MMY3008) study of daratumumab in combination with lenalidomide and dexamethasone as treatment for patients with newly diagnosed multiple myeloma, who are not candidates for high dose chemotherapy and ASCT. Data from this study was presented as a Late-Breaking Abstract at the 2018 American Society o
-
Dejligt!
-
Fedt!
-
Ikke noget hurlumhej med sc, men soc har også ret
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind